Key result
Next-generation sequencing of liposarcoma identifies actionable targets yielding a 23-month median progression time on MDM2 inhibitors.
Why the study?
Does next-generation sequencing identify actionable targets and guide therapy in well-differentiated/dedifferentiated liposarcoma?
Population
20 patients with well-differentiated/dedifferentiated liposarcoma who had their tumor sequenced by either…
Design
Cohort
Authors
Loading...
Does not support routine NGS-guided MDM2 inhibition; leaves open efficacy pending randomized trials.
Observational (n=20)
No
Does next-generation sequencing identify actionable targets and guide therapy in well-differentiated/dedifferentiated liposarcoma?
Next-generation sequencing in well-differentiated/dedifferentiated liposarcoma identifies universal MDM2/CDK4 amplification and novel mutations, with MDM2 inhibitors showing potential clinical benefit.
Somaiah et al. (2018) conducted an observational in Well-differentiated/dedifferentiated liposarcoma (n=20). Next-generation sequencing was evaluated on Median time to progression on MDM2 inhibitor (95% CI 10-83). Next-generation sequencing of liposarcoma identified actionable targets; 8 patients treated with an MDM2 inhibitor had a median time to progression of 23 months (95% CI 10-83).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: